Document Detail


Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography.
MedLine Citation:
PMID:  19680260     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We investigated the impact of lowering blood pressure (BP) with azelnidipine, a newly developed calcium channel blocker, generation on the left ventricular (LV) diastolic function and LV filling pressure by assessing non-invasive indices derived from echo Doppler study. This study evaluated 232 hypertensive patients with diastolic dysfunction. This study had two groups: (1) in which azelnidipine was administered to patients as a first-line therapy, and (2) in which amlodipine was converted to azelnidipine. Early diastolic mitral annulus velocity (e', cm s(-1)), the ratio of peak E velocity to e' velocity (E/e' ratio) and level of brain natriuretic peptide (BNP) were measured before and, an average of, 8 months after azelnidipine treatment. In the first-line azelnidipine group, the systolic and diastolic BP reduced by 26 and 11 mm Hg, respectively. The e' increased, and E/e' ratio and BNP level decreased significantly. In the converted-from-amlodipine group, the systolic and diastolic BP decreased by 14 and 6 mmHg, respectively. The e' velocity increased, but the E/e' ratio and BNP level did not change. In both groups, azelnidipine lowered BP and improved LV diastolic function (an increase in the e' velocity). Possible reduction in LV filling pressure (a decrease in the E/e' ratio and BNP level) is observed only in the first-line azelnidipine group.
Authors:
Hiroshi Ito; Katsuhisa Ishii; Katsuomi Iwakura; Fumiaki Nakamura; Toshihiko Nagano; Shin Takiuchi
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-08-14
Journal Detail:
Title:  Hypertension research : official journal of the Japanese Society of Hypertension     Volume:  32     ISSN:  1348-4214     ISO Abbreviation:  Hypertens. Res.     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-10-07     Completed Date:  2009-12-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9307690     Medline TA:  Hypertens Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  895-900     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, Okayama University, Graduate School of Medicine, Okayama, Japan. itomd@md.okayama-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Azetidinecarboxylic Acid / analogs & derivatives*,  therapeutic use
Calcium Channel Blockers / therapeutic use*
Dihydropyridines / therapeutic use*
Drug Therapy, Combination
Female
Humans
Hypertension / drug therapy*,  physiopathology,  ultrasonography*
Hypertrophy, Left Ventricular / drug therapy,  ultrasonography
Male
Middle Aged
Natriuretic Peptide, Brain / metabolism
Ventricular Dysfunction, Left / drug therapy*,  physiopathology,  ultrasonography*
Ventricular Function, Left / drug effects
Young Adult
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Dihydropyridines; 114471-18-0/Natriuretic Peptide, Brain; 123524-52-7/azelnidipine; 2517-04-6/Azetidinecarboxylic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intermedin is upregulated and has protective roles in a mouse ischemia/reperfusion model.
Next Document:  Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic ...